ArticleFrontiers in oncology2026
SYTL5 drives malignant progression in differentiated thyroid carcinoma: unveiling its regulatory mechanisms.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the expression of SYTL5 in differentiated thyroid carcinoma (DTC) and elucidate its clinical significance and underlying molecular mechanisms. Methods: SYTL5 expression in 107 paired DTC and adjacent normal tissues was evaluated by immunohistochemistry, qRT-PCR, and Western blot. Associations with clinicopathological variables were assessed using chi-square or Fisher's exact tests with Benjamini-Hochberg false discovery rate adjustment, and the distant metastasis subgroup was summarized descriptively because only one M1 case was available. Stable SYTL5 knockdown or overexpression DTC cell lines were established using RNA interference and lentiviral transfection. Cell proliferation, apoptosis, invasion, and migration were assessed using EdU staining, flow cytometry, and Transwell assays. A nude mouse subcutaneous xenograft model was constructed to evaluate tumor growth Results: SYTL5 expression was significantly upregulated in DTC tissues and was positively associated with lymph node metastasis after false discovery rate adjustment. SYTL5 silencing inhibited DTC cell proliferation, invasion, and migration while modestly increasing apoptosis, whereas SYTL5 overexpression exerted opposite effects. Mechanistically, SYTL5 knockdown was associated with reduced TGFBR2 and phosphorylated Smad3 expression without affecting total Smad3 levels, both Conclusion: SYTL5 is associated with DTC progression and lymph node metastasis and functionally supports malignant phenotypes in DTC models. The data support a ZNF384-SYTL5-TGFBR2/Smad3 regulatory axis, while direct regulation of TGFBR2 by SYTL5 and the contribution of Smad2 or non-canonical pathways require further study. SYTL5 may represent a candidate therapeutic target for DTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.